Myongji Hospital
Myongji Hospital
République de Corée, Goyang
Kim Jong Yeon
23 années d'expérience
La clinique est certifiée :
| République de Corée | Turquie | Espagne | |
| Thérapie hormonale | de $2,000 | de $406 | de $3,000 |
| Thérapie ciblée | de $5,500 | de $1,000 | de $15,000 |
| Résection de la vésicule biliaire | de $5,800 | de $4,050 | de $3,000 |
| Résection de l'intestin grêle | de $74 | de $3,829 | de $18,000 |
| Résection de l'estomac | de $18,500 | de $12,000 | de $9,000 |
Bookimed ne rajoute pas de frais pour les traitements de Gastro-entérologie. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Gastro-entérologie et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Gastro-entérologie.
Professor Kim Jong-yeon is a gastroenterologist at Myongji Hospital. He treats diseases of the esophagus, stomach, colon, and liver, including cirrhosis and hepatitis. He performs therapeutic endoscopy, such as endoscopic polypectomy. He also serves as Deputy Director of the International Healthcare Center.
He is a member of the Liver Failure Center. He works with teams in hepatology, liver cancer, and transplantation to provide coordinated care for advanced liver disease and for transplant candidates.
MD, Jeonbuk National University College of Medicine. Clinical Professor of Gastroenterology at Myongji Hospital. Member of the Korean Association of Internal Medicine, the Korean Society of Gastroenterology, and the Korean Society of Gastrointestinal Endoscopy. Former resident and fellow at Inje University Ilsan Paik Hospital.
Professor Park Jung-won is a leading Korean specialist in hepatocellular carcinoma with over 30 years of experience. He is the Director of the Liver and Liver Cancer Center and the Integrated Cancer Care Center at Myongji Hospital. He led Korea’s first HCC guidelines in 2003. He has also overseen their updates for about 20 years. His team validated proton beam radiotherapy for liver cancer, as published in the Journal of Hepatology. He has authored more than 200 SCI-indexed papers. He also helped lead global trials, including the 2025 CheckMate 9DW study, which showed improved outcomes with nivolumab plus ipilimumab for unresectable HCC.
MD/PhD, Seoul National University; Member, National Academy of Medicine of Korea; former President, Korean Liver Cancer Association; Chair, Korean HCC Guidelines Committee; Prime Minister’s and Health Minister’s commendations; Pfizer Medical Research Award and Roche Oncology Academic Award.